Correction (DOI:10.1016/j.jamcollsurg.2009.07.018);The "Off-Label" Role of Recombinant Factor VIIa in Surgery: Is the Problem Deficient Evidence or Defective Concept?

Journal of the American College of Surgeons

Volumn 209, Issue 5, 2009, Pages 659-667

  Al Ruzzeh, Sharif ^a   Navia, Jose L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLUNT TRAUMA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; DISABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; HEART SURGERY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; INJURY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER RESECTION; LIVER SURGERY; LIVER TRANSPLANTATION; MORTALITY; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PELVIS FRACTURE; PENETRATING TRAUMA; PRIORITY JOURNAL; REVIEW; SURGICAL PATIENT; TREATMENT OUTCOME;

BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; COAGULANTS; DRUG LABELING; FACTOR VIIA; HEPATECTOMY; HUMANS; LIVER TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SURGICAL PROCEDURES, OPERATIVE; TRAUMATOLOGY;

EID: 70350221908     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2009.11.013     Document Type: Erratum

References (66)

1. Hedner U., and Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patient with high-titer inhibitors. J Clin Invest 71 (1983) 1836-1841
2. O'Connell K., Wood J., Wise R., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006) 293-298
3. Kenet G., Walden R., Eldad A., and Matinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354 (1999) 1879
4. White B., McHale J., Ravi N., et al. Successful use of recombinant FVIIa (Novoseven®) in the treatment of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 107 (1999) 677-678
5. Hedner U., and Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu Rev Med 59 (2008) 29-41
6. Lak M., Scharling B., Blemings A., et al. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Haemophilia 14 (2008) 103-110
7. Jurlander B., Thim L., Klausen N.K., Persson, et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 27 (2001) 373-384
8. Veldman A., Hoffman M., and Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 10 (2003) 797-811
9. Viles-Gonzalez J., Anand S., Zafar M., et al. Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis. J Cardiovasc Pharmacol 43 (2004) 669-676
10. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 17 Suppl (2003) S1-S5
11. Meng Z., Wolberg A., Monroe D., and Hoffman M. The effect of temperature and pH on the activity of factor VIIa in hypothermic and acidotic patients. J Trauma 55 (2003) 886-891
12. Martinowitz U., and Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 3 (2005) 640-648
13. Lewis N., Brunker P., Lemire S., and Kaufman R. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage. Transfusion 49 (2009) 689-695
14. Schwartz R., Abildgaard C., Aledort L., et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 323 (1990) 1800-1805
15. Senzolo M., Burra P., Cholongitas E., and Burroughs A.K. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 12 (2006) 7725-7736
16. Ferro D., Quintarelli C., Lattuada A., et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 23 (1996) 1377-1383
17. Yorke A., and Mant M. Factor VII deficiency and surgery. Is preoperative replacement therapy necessary?. JAMA 238 (1977) 424-425
18. Ben-Ari Z., Panagou M., Patch D., et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 26 (1997) 554-559
19. Wanless I., Wong F., Blendis L., et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 21 (1995) 1238-1247
20. Biagini M., Tozzi A., Marcucci R., et al. Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis. World J Gastroenterol 12 (2006) 1607-1612
21. Papatheodoridis G., Papakonstantinou E., Andrioti E., et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 52 (2003) 404-409
22. Tripodi A., Salerno F., Chantarangkul V., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 41 (2005) 553-558
23. The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. Hepatology 14 (1991) 1016-1024
24. D'Amico G., De Franchis R., and Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 38 (2003) 599-612
25. Bosch J., Thabut D., Bendtsen F., et al., European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 127 (2004) 1123-1130
26. Planinsic R., van der Meer J., Testa G., et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 11 (2005) 895-900
27. Lodge J., Jonas S., Jones R., et al., rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 11 (2005) 973-979
28. Hendriks H., Meijer K., de Wolf J., et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 71 (2001) 402-405
29. Jeffers L., Chalasani N., Balart L., et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 123 (2002) 118-126
30. Lodge J., Jonas S., Oussoultzoglou E., et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 102 (2005) 269-275
31. Shao Y., Yang J., Chau G., et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 191 (2006) 245-249
32. Páramo J., and Rocha E. Hemostasis in advanced liver disease. Semin Thromb Hemost 19 (1993) 184-190
33. Joist J. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 94 (1999) 2801-2803
34. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 119 (2007) 643-651
35. Jabbour N., Gagandeep S., Mateo R., et al. Live donor liver transplantation without blood products: strategies developed for Jehovah's Witnesses offer broad application. Ann Surg 240 (2004) 350-357
36. Jabbour N., Gagandeep S., Shah H., et al. Impact of a transfusion-free program on non-Jehovah's Witness patients undergoing liver transplantation. Arch Surg 14 (2006) 913-917
37. Singer A., Olthoff K., Kim H., et al. Role of plasmapheresis in the management of acute hepatic failure in children. Ann Surg 234 (2001) 418-424
38. Hattori T., Khan M., Colman R., and Edmunds L. Plasma tissue factor plus activated peripheral mononuclear cells activate factors VII and X in cardiac surgical wounds. J Am Coll Cardiol 46 (2005) 707-713
39. Erlich J., Boyle E., Labriola J., et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 157 (2000) 1849-1862
40. Bevan D. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 104 (1999) 208-219
41. Philippou H., Davidson S., Mole M., et al. Two-chain factor VIIa generated in the pericardium during surgery with cardiopulmonary bypass. Relationship to increased thrombin generation and heparin concentration. Arterioscler Thromb Vasc Biol 19 (1999) 248-254
42. Avidan M., Levy J., Scholz J., et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anaesthesiology 102 (2005) 276-284
43. Gill R., and Herbertson M. Recombinant factor VIIa: a universal haemostatic agent?. Ann Cardiac Anaesth 9 (2006) 97-99
44. Rosenthal C., Volk T., Spies C., et al. Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: perioperative treatment with factor VII concentrate. Thromb Haemost 98 (2007) 900-902
45. Avci Z., Malbora B., and Gokdemir M. Successful use of recombinant factor VIIa (NovoSeven®) during cardiac surgery in a pediatric patient with congenital factor XI deficiency. Pediatr Cardiol 29 (2008) 220-222
46. Raivio P., Suojaranta-Ylinen R., and Kuitunen A. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 80 (2005) 66-71
47. Clark A., Gordon W., Walker I., and Tait R. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 86 (2004) 120-124
48. Diprose P., Herbertson M., O'Shaughnessy D., and Gill R. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 95 (2005) 596-602
49. Ekert H., Brizard C., Eyers R., et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 17 (2006) 389-395
50. Karkouti K., Beattie W., Crowther M., et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anaesth 54 (2007) 573-582
51. Guyatt G., Gutterman D., Baumann M., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129 (2006) 174-181
52. Brohi K., Cohen M., and Davenport R. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 13 (2007) 680-685
53. Hess J. Blood and coagulation support in trauma care. Hematology Am Soc Hematol Educ Program (2007) 187-191
54. Brohi K., Singh J., Heron M., and Coats T. Acute traumatic coagulopathy. J Trauma 54 (2003) 1127-1130
55. Brohi K., Cohen M., Ganter M., et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 64 (2008) 1211-1217
56. Cohen M., Brohi K., Ganter M., et al. Early coagulopathy after traumatic brain injury: the role of hypoperfusion and the protein C pathway. J Trauma 63 (2007) 1254-1262
57. Boffard K., Riou B., Warren B., et al., NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59 (2005) 8-18
58. Rizoli S., Boffard K., Riou B., et al., NovoSeven Trauma Study Group. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care 10 (2006) R178
59. Raobaikady R., Redman J., Ball J., et al. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 94 (2005) 586-591
60. Rotondo M., Schwab C., McGonigal M., et al. 'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma 35 (1993) 375-382
61. Hirshberg A., Sheffer N., and Barnea O. Computer simulation of hypothermia during "damage control" laparotomy. World J Surg 23 (1999) 960-965
62. Mayer S., Brun N., Begtrup K., et al., Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352 (2005) 777-785
63. Mayer S., and FAST Trial Steering Committee. Complications in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology 69 (2007) 319-320
64. Mannucci P. Intracerebral haemorrhage and recombinant factor VIIa: not so good news!. Intern Emerg Med 2 (2007) 235-236
65. Monroe D., and Key N. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 5 (2007) 1097-1105
66. Gando S., Kameue T., Sawamura A., et al. An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery. Thromb Res 120 (2007) 87-93